There is a fascinating comment by Kattan scheduled for publication in a forthcoming issue of the new journal Urology Practice. It makes a truly critical point about whether any of the new biomarkers are actually adding significantly to what we know about how to assess risk for prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: accuracy, biomarket, endpoint, PSA, risk, test | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 